Polymer-conjugated paclitaxel as a radiosensitizing agent--a big step forward for combined modality therapy?
Tishler
Roy B
RB
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011099:Polyglutamic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000031:analogs & derivatives; D011838:Radiation-Sensitizing Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D043823:Taxoids
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D011099:Polyglutamic Acid; D017239:Paclitaxel; C509139:paclitaxel poliglumex